BRPI0918580A2 - polimorfo b da n-(2-aminofenil)-4-(n-(piridina-3-il)-metoxicarbonil-aminometil)-benzamida (ms-275) - Google Patents

polimorfo b da n-(2-aminofenil)-4-(n-(piridina-3-il)-metoxicarbonil-aminometil)-benzamida (ms-275)

Info

Publication number
BRPI0918580A2
BRPI0918580A2 BRPI0918580A BRPI0918580A BRPI0918580A2 BR PI0918580 A2 BRPI0918580 A2 BR PI0918580A2 BR PI0918580 A BRPI0918580 A BR PI0918580A BR PI0918580 A BRPI0918580 A BR PI0918580A BR PI0918580 A2 BRPI0918580 A2 BR PI0918580A2
Authority
BR
Brazil
Prior art keywords
aminophenyl
methoxycarbonyl
aminomethyl
pyridin
benzamide polymorph
Prior art date
Application number
BRPI0918580A
Other languages
English (en)
Inventor
Gabriele Winter
Jens Geisler
Matthias Schneider
Michael Gottfried
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41133825&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0918580(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of BRPI0918580A2 publication Critical patent/BRPI0918580A2/pt
Publication of BRPI0918580A8 publication Critical patent/BRPI0918580A8/pt
Publication of BRPI0918580B1 publication Critical patent/BRPI0918580B1/pt
Publication of BRPI0918580B8 publication Critical patent/BRPI0918580B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0918580A 2008-08-29 2009-08-27 polimorfo cristalino b da n-(2-aminofenil)-4-[n-(piridina3-il)metóxi-carbonilaminometil]-benzamida, composição e combinação contendo o mesmo, uso e seu processo de produção BRPI0918580B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9304608P 2008-08-29 2008-08-29
EP08163274.7 2008-08-29
EP08163274 2008-08-29
US61/093,046 2008-08-29
PCT/EP2009/006381 WO2010022988A1 (en) 2008-08-29 2009-08-27 N-(2-aminophenyl)-4-[n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (ms-275)polymorph b

Publications (4)

Publication Number Publication Date
BRPI0918580A2 true BRPI0918580A2 (pt) 2015-12-01
BRPI0918580A8 BRPI0918580A8 (pt) 2017-07-11
BRPI0918580B1 BRPI0918580B1 (pt) 2020-11-24
BRPI0918580B8 BRPI0918580B8 (pt) 2021-05-25

Family

ID=41133825

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0918580A BRPI0918580B8 (pt) 2008-08-29 2009-08-27 polimorfo cristalino b da n-(2-aminofenil)-4-[n-(piridina3-il)metóxi-carbonilaminometil]-benzamida, composição e combinação contendo o mesmo, uso e seu processo de produção

Country Status (35)

Country Link
US (2) US7973166B2 (pt)
EP (1) EP2350005B1 (pt)
JP (1) JP4921616B2 (pt)
KR (1) KR101073760B1 (pt)
CN (1) CN102137846B (pt)
AR (1) AR073226A1 (pt)
AT (1) ATE538094T1 (pt)
AU (1) AU2009286982C1 (pt)
BR (1) BRPI0918580B8 (pt)
CA (1) CA2735294C (pt)
CO (1) CO6351736A2 (pt)
CR (2) CR20110107A (pt)
CY (1) CY1112645T1 (pt)
DK (1) DK2350005T3 (pt)
DO (1) DOP2011000064A (pt)
EA (1) EA016811B1 (pt)
EC (1) ECSP11010849A (pt)
ES (1) ES2378640T3 (pt)
HN (1) HN2011000609A (pt)
HR (1) HRP20120183T8 (pt)
IL (1) IL211276A (pt)
MA (1) MA32610B1 (pt)
MX (1) MX2011002248A (pt)
MY (1) MY149058A (pt)
NZ (1) NZ591387A (pt)
PE (2) PE20141062A1 (pt)
PL (1) PL2350005T3 (pt)
PT (1) PT2350005E (pt)
RS (1) RS52164B (pt)
SI (1) SI2350005T1 (pt)
SM (1) SMT201200026B (pt)
SV (1) SV2011003846A (pt)
TW (1) TWI427062B (pt)
WO (1) WO2010022988A1 (pt)
ZA (1) ZA201102285B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20141062A1 (es) 2008-08-29 2014-09-19 Bayer Ip Gmbh Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil]benzamida (ms-275)
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
FR2977492B1 (fr) * 2011-07-04 2013-07-05 Servier Lab Nouvelle association entre le n-hydroxy-4-{2-[3-(n,n-dimethylaminomethyl) benzofuran-2-ylcarbonylamino]ethoxy}benzamide et le folfox
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
WO2016077451A1 (en) 2014-11-12 2016-05-19 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
EP3168210A1 (en) 2015-11-13 2017-05-17 Sandoz Ag Crystalline forms of entinostat
WO2017216761A1 (en) * 2016-06-17 2017-12-21 Dr. Reddy's Laboratories Limited Solid forms of entinostat
CN110944978A (zh) * 2017-07-28 2020-03-31 杭州领业医药科技有限公司 含恩替诺特的化合物,其化合物晶型及其制备方法和药物组合物
JP2024517919A (ja) 2021-05-10 2024-04-23 マクファーラン スミス リミテッド エンチノスタットの新規形態

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
JP3354090B2 (ja) * 1996-09-30 2002-12-09 シエーリング アクチエンゲゼルシャフト 分化誘導剤
US6320078B1 (en) * 1998-07-24 2001-11-20 Mitsui Chemicals, Inc. Method of producing benzamide derivatives
JP4030683B2 (ja) * 1998-07-24 2008-01-09 三井化学株式会社 ベンズアミド誘導体の合成法
JP2001064177A (ja) * 1999-08-16 2001-03-13 Schering Ag ベンズアミド誘導体を有効成分とする製剤
JP4360660B2 (ja) * 1999-11-09 2009-11-11 三井化学株式会社 モノアシルフェニレンジアミン誘導体の精製法
PE20050206A1 (es) * 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
PE20141062A1 (es) 2008-08-29 2014-09-19 Bayer Ip Gmbh Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil]benzamida (ms-275)

Also Published As

Publication number Publication date
WO2010022988A1 (en) 2010-03-04
PT2350005E (pt) 2012-03-12
EA016811B1 (ru) 2012-07-30
MX2011002248A (es) 2011-03-29
SV2011003846A (es) 2011-07-27
CR20160465A (es) 2016-12-06
DOP2011000064A (es) 2011-03-31
USRE45499E1 (en) 2015-04-28
HK1160107A1 (en) 2012-08-10
AR073226A1 (es) 2010-10-20
SMT201200026B (it) 2012-07-10
AU2009286982A1 (en) 2010-03-04
MA32610B1 (fr) 2011-09-01
KR20110038187A (ko) 2011-04-13
NZ591387A (en) 2012-03-30
IL211276A0 (en) 2011-04-28
DK2350005T3 (da) 2012-03-19
TWI427062B (zh) 2014-02-21
RS52164B (sr) 2012-08-31
ATE538094T1 (de) 2012-01-15
ZA201102285B (en) 2011-12-28
PE20141062A1 (es) 2014-09-19
BRPI0918580B1 (pt) 2020-11-24
CO6351736A2 (es) 2011-12-20
ECSP11010849A (es) 2011-03-31
CA2735294A1 (en) 2010-03-04
HRP20120183T1 (hr) 2012-03-31
HRP20120183T8 (en) 2012-11-30
SI2350005T1 (sl) 2012-03-30
US7973166B2 (en) 2011-07-05
BRPI0918580B8 (pt) 2021-05-25
PL2350005T3 (pl) 2012-05-31
CN102137846B (zh) 2014-04-23
CA2735294C (en) 2013-10-15
ES2378640T3 (es) 2012-04-16
TW201014820A (en) 2010-04-16
HN2011000609A (es) 2014-09-29
CR20110107A (es) 2011-04-28
CN102137846A (zh) 2011-07-27
EP2350005A1 (en) 2011-08-03
JP2012500819A (ja) 2012-01-12
EP2350005B1 (en) 2011-12-21
MY149058A (en) 2013-07-15
PE20110677A1 (es) 2011-09-16
EA201100354A1 (ru) 2011-10-31
CY1112645T1 (el) 2016-02-10
AU2009286982C1 (en) 2012-04-26
JP4921616B2 (ja) 2012-04-25
BRPI0918580A8 (pt) 2017-07-11
US20100056585A1 (en) 2010-03-04
IL211276A (en) 2014-07-31
KR101073760B1 (ko) 2011-10-13
AU2009286982B2 (en) 2011-06-23

Similar Documents

Publication Publication Date Title
BRPI0918580A2 (pt) polimorfo b da n-(2-aminofenil)-4-(n-(piridina-3-il)-metoxicarbonil-aminometil)-benzamida (ms-275)
EP2298731A4 (en) AMIDE COMPOUND
DK2089364T3 (da) Pyridinonforbindelser
DK3338790T3 (da) Oligopeptid-forbindelser og anvendelser deraf
DK2170828T3 (da) Substituerede n-aryl pyridinoner som fibrotiske inhibitorer
ZA201004732B (en) Novel n-(2-amino-phenyl)-amide derivatives
EP2114634A4 (en) TESTING HEAD MANIPULATOR
NO20091424L (no) Substituerte amider, fremgangsmåte for fremstilling derav og anvendelse derav
NO20091426L (no) Substituerte amider, fremgangsmåte for fremstilling derav og anvendelse derav
DK2229572T3 (da) Rekuperator
LT2349238T (lt) Tramadolio ir nsaid junginių ko-kristalai
BRPI0818348A2 (pt) Derivados de n-(pirazol-3-il)-benzamida como ativadores de glicocinase
BRPI0909159A2 (pt) inibidores baseados em hidroxamato de desacetilases b
EP2213238A4 (en) Imaging device
DK1903134T3 (da) Elastisk fiberdug og fremgangsmåde til fremstilling heraf
DK2156456T3 (da) Koblingsapparatur
EP2087842A4 (en) IMAGING DEVICE
BRPI0910931A2 (pt) ciclopentanos substituídos terapêuticos
BRPI0912399A2 (pt) n-(2-amino-fenil)-acrilamidas
BRPI0822288A2 (pt) tijolo perfurado
DK2350079T3 (da) Thiazolylpyrazolopyrimidinforbindelser som syntetiske mellemprodukter og dertil relaterede syntetiske fremgangsmåder
EP2016256A4 (en) HEAD OF ORIENTATION
GB2462893B (en) N-(2-aminophenyl)-4-[N-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B
ES1067268Y (es) Bufanda con aplicacion terapeutica
FI20075945L (fi) Lohkokahmari

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: BAYER PHARMA AKTIENGESELLSCHAFT (DE)

B25A Requested transfer of rights approved

Owner name: BAYER INTELLECTUAL PROPERTY GMBH (DE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/08/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25G Requested change of headquarter approved

Owner name: BAYER INTELLECTUAL PROPERTY GMBH (DE)